Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Amgen to Open China R&D Center at ShanghaiTech

By R&D Editors | September 26, 2013

Amgen and ShanghaiTech University today announced the two organizations have entered into a memorandum of understanding (MOU) to form a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China. This agreement includes plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University.

 
“Amgen and ShanghaiTech University share mutual goals of scientific excellence and rigor and will benefit from each other’s strength and expertise in advancing biopharmaceutical discovery in China,” said Sean Harper, executive vice president of Research and Development at Amgen. “Expansion into China is a business priority for Amgen and opening this R&D center is another clear and important step forward in Amgen’s commitment to the China market.”
 
Under the terms of the MOU, Amgen will co-locate its China R&D center with ShanghaiTech University’s two life science institutes: the Shanghai Institute for Advanced Immunochemical Studies (SIAIS) and the iHuman Institute.
 
“We are pleased to be partnering with Amgen,” said Professor Mianheng Jiang, chairman of Executive Committee of ShanghaiTech University. “ShanghaiTech aims to build a research-oriented university that provides a dynamic approach to learning and ultimately solving problems facing society. This partnership is a commitment to develop more effective bio-medicine for the benefits of the patients in China and in the whole world.”
 
“We are excited about this unique opportunity to work with ShanghaiTech University,” added Mingqiang Zhang, vice president of China Research and Development at Amgen. “The combination of Amgen’s industry-leading expertise in biopharmaceuticals and the world-class academic excellence of scientists at the SIAIS and iHuman institutes of ShanghaiTech will be a very powerful force in advancing drug discovery and development. We aim to address unmet medical needs that are particularly relevant for patients in China.”
 
“We are delighted that Amgen, a key player in the global biologics sector, will be co-locating its China R&D center at ShanghaiTech University,” said Professor Richard Lerner, founding director of Shanghai Institute for Advanced Immunochemical Studies, an antibody research institute of ShanghaiTech University. “We aim to become one of the world’s leading antibody research institutes and the co-location of Amgen’s China R&D center with us will help to steer our research to be more applicable and to ultimately help patients in the fight against serious illnesses.”
 
Amgen expects its China R&D center will be fully operational in 2014.
 
Date: September 24, 2013
Source: Amgen

Related Articles Read More >

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE